Clinical Trials Logo
  1. Home
  2. Tick-Borne Encephalitis
  3. NCT05607394

Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric Cases — TBE-KID  

Tick-borne Encephalitis Clinical Trial

Official title:
Prevalence of Tick-borne Encephalitis (TBE) in the Pediatric Population Treated at the University Hospitals of Strasbourg (HUS) and Characterization of Confirmed Pediatric Cases

Clinical Trial Summary

Tick-borne encephalitis (TBE) is a zoonosis mainly transmitted to humans by the bite of ticks of the genus Ixodes and, to a lesser extent, by the consumption of contaminated and unpasteurized dairy products. During the last decade, the epidemiology of this arbovirosis has changed profoundly with the discovery of new human cases and/or new areas of circulation of tick-borne encephalitis virus (TBEV) throughout Europe and particularly in France. Historically, Alsace is the main endemic area for this pathology in France. The pathology is notifiable since June 2021 in France. Although TBEV infection in children seems to lead to a milder clinical presentation, data are much less abundant than in adults and only a few cases reported in infants under 1 year old have been published. Data from the most recent ECDC Annual Epidemiological Report on TBE (2019) showed incidence rates of approximately 0.2 and 0.5 per 100,000 population in patients younger than 5 and 15 years, respectively. However, several observations may moderate and challenge both the low incidence rate and the less severe clinical presentation reported in children

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05607394
Study type Observational
Source University Hospital, Strasbourg, France
Contact Aurélie Velay-Rusch, MD
Phone 33 3 69 55 14 40
Email aurelie.velay@chru-strasbourg.fr
Status Recruiting
Phase
Start date October 24, 2022
Completion date October 24, 2023
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01031537 - Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) Phase 2
Recruiting NCT02463942 - Tick-borne Encephalitis and Positive Borrelial Antibodies N/A
Completed NCT01361776 - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Phase 2/Phase 3
Completed NCT00161863 - Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years Phase 3
Completed NCT00161798 - Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. Phase 2
Completed NCT01710189 - Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac Phase 4
Completed NCT00161772 - Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. Phase 2
Completed NCT00161785 - Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Phase 4
Completed NCT00118924 - Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults Phase 1
Recruiting NCT05941546 - Tick-borne Encephalitis Virus Research in Limousin
Not yet recruiting NCT04573205 - Primary TBE Vaccination for the Elderly Phase 4
Completed NCT02318069 - New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Phase 2/Phase 3
Completed NCT04648241 - Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older Phase 3
Completed NCT00804219 - Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination Phase 4